Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus [documento electrónico] / Luis Fernando Pinto Peñaranda, ; Carlos Jaime Velásquez Franco, ; Carolina Prieto Saldarriaga, ; Javier Darío Márquez Hernández,  . - 2011.
Obra : Lupus

Idioma : Inglés (eng)

Palabras clave :	Nephritis  rituximab  systemic lupus erythematosus
Resumen :	Despite aggressive treatment for systemic lupus erythematosus (SLE) with high-dose glucocorticoids and immunosuppressive agents, a significant proportion of patients persist with activity or relapse. Although the results from randomized studies showed no beneficial effects of rituximab (RTX) in SLE, this treatment has proven promising results in open label trials including patients with severe and refractory disease. We report a prospective cohort of 42Colombian patients with severe and refractory SLE treated with RTX after failure response to glucocorticoids and, at least, another immunosuppressive drug. We observed a reduction in steroid requirement [47.4 mg/day at 24 months (p
Mención de responsabilidad :	L F Pinto, C J Velásquez, C Prieto, L Mestra, E Forero, J D Márquez
Referencia :	Lupus. 2011 Oct;20(11):1219-26.
DOI (Digital Object Identifier) :	10.1177/0961203311409273
PMID :	21784778
En línea :	https://journals.sagepub.com/doi/10.1177/0961203311409273
Enlace permanente :	https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3564